MZe786

MZe786 is a novel small molecule drug described as a hydrogen sulfide (H₂S)-releasing aspirin derivative. It is chemically engineered to release both acetylsalicylic acid (aspirin) and hydrogen sulfide in vivo. The primary mechanism of action involves the upregulation of antioxidant defense genes and inhibition of soluble fms-like tyrosine kinase 1 (sFlt-1), which are implicated in the pathogenesis of preeclampsia—a life-threatening hypertensive disorder of pregnancy. In preclinical models, MZe786 has been shown to reduce maternal hypertension, prevent major organ damage (notably renal injury), improve fetal weight and survival, and decrease circulating sFlt-1 levels more effectively than standard aspirin therapy. The drug is being developed primarily for the prevention and treatment of preeclampsia but may have broader applications in disorders characterized by oxidative stress or angiogenic imbalance[1][2][3][6].

Other names

hydrogen sulfide-releasing aspirinH2S-releasing aspirinH-2S-releasing aspirinH 2S-releasing aspirin2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl ester